# Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

> **NCT01327235** · PHASE2 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 336 (actual)

## Conditions studied

- Malignant Pleural Effusion
- Malignant Ascites

## Interventions

- **DRUG:** Endostar
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01327235
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-07
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2014-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327235, "Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01327235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*